In this article, I will explain—using back-of-the-envelope math and plain English—why the stock of Viking Therapeutics, Inc. (NASDAQ: VKTX ), one of the frontrunners in the GLP-1 weight-loss drug market, may represent a (relatively) de-risked investment opportunityI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been ope ...

Key Points Novartis and Gilead Sciences have businesses that can perform well during downturns. Novartis has an extensive portfolio of medicines across many therapeutic areas. Gilead Sciences leads the HIV market and is expanding its oncology lineup. 10 stocks we like better than Novartis › Equity markets experienced significant volatility this year. Many investors feared that President Donald Trump's aggressive trade policies would plunge the economy into a recession and lead to a full-blown sto ...

Earn free CE credits and discover new strategies For more news, information, and strategy, visit the Leveraged & Inverse Content Hub. Originally published September 29, 2025 First Fed Cut – The Federal Reserve lowered interest rates by 0.25% on September 17, 2025, which is the first cut since December 18, 2024. The only committee member voting against the cut was Stephen I. Miran, who wanted a 0.5% cut (source: Federal Reserve). Another Acquisition – Pfizer announced the acquisition of Metsera, a weight-l ...

, /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have untilNovember 17, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cytokinetics, Incorporated (NasdaqGS: CYTK), if they purchased or otherwise acquired the Company's securities between December 27, 2023 and May 6, 2025, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California. On this news, the p ...

市场驱动因素 - 市场上涨由持怀疑态度的专业基金经理和涌入的业余投资者共同推动 专业基金经理担忧市场涨幅过大 但业余投资者对个股的热情持续推动市场走强 [1][2] - 临近年底 专业基金经理可能改变策略进行买入 以向股东证明其未错过市场最大赢家 [2] - 当前市场存在显著的害怕错过情绪 今日几乎所有资产类别均上涨 包括加密货币和黄金等被专业人士视为高估的资产 [3] 市场表现 - 今日道琼斯指数上涨239点 纳斯达克指数上涨28% 标准普尔指数上涨001% [1] - 数据中心、核反应堆铀燃料、量子计算等领域股票出现爆发式上涨 表现异常强劲 [3] - 大型制药股表现突出 持续上涨 此前总统与辉瑞公司达成协议 使药企受药品价格回调计划的影响看似不大 [6] 行业动态 - 专业人士认为数据中心等板块存在泡沫 希望相关股票降温 但认为这些股票估值过高 却无法做空打压 [3][4] - 当前市场处于财报空窗期 缺乏重要财报发布 动量主要来自被交易类公司吸引的个体投资者 [5] - Robin Hood和Coinbase等交易平台类公司引领涨势 [5] 未来展望 - 预计总统将与至少另一家制药公司达成协议 这可能在下一周发生 [6]

股价显著下跌公司概览 - Titan Pharmaceuticals Inc (NASDAQ:TTNP) 股价大幅下跌43.08%至13.65美元，可能与KE Sdn Bhd的拟议合并案及相关调查有关 [2][7] - American Rebel Holdings Inc (NASDAQ:AREB) 股价下跌42.07%至10.77美元，尽管公司通过Champion Safe Company与Guardian Lock & Security合作以扩展经销商网络 [3][7] - bioAffinity Technologies Inc (BIAFW) 股价下跌33.36%至0.25美元，公司专注于非侵入性癌症诊断与治疗，近期发布了CyPath® Lung在早期肺癌检测中的临床价值案例研究 [4][7] - Leap Therapeutics Inc (NASDAQ:LPTX) 股价下跌29.78%至0.51美元，公司计划在2025年ESMO大会上公布DeFianCe研究中DKN-01联合疗法治疗晚期结直肠癌的最终临床数据 [5][7] 股价波动潜在原因 - 公司特定事件如合并调查（Titan Pharmaceuticals）和临床数据更新（Leap Therapeutics）是影响股价的关键因素 [2][5] - 战略举措如扩展经销商网络（American Rebel Holdings）未能抵消更广泛的市场情绪或内部发展的负面影响 [3][7] - 行业趋势及投资者对临床进展公告的反应（bioAffinity Technologies, Leap Therapeutics）可能导致股价波动 [4][5] - 股价变动反映了股票市场的波动性，受公司发展、行业趋势及更广泛经济因素的综合影响 [6]

公司财务业绩与展望 - 公司下调全年调整后每股收益预测至1038美元至1058美元 较此前预测的1188美元至1208美元大幅降低[2] - 公司预计第三季度调整后每股收益为174美元至178美元 远低于分析师预期的327美元[4] - 下调原因主要与第三季度预计将计入27亿美元的在研项目研发费用有关[1] 在研项目研发费用 - 该费用可能产生于合作、许可协议或资产收购 但由于时间和发生的不确定性通常不予预测[2] - 公司未具体说明此次27亿美元费用的产生原因[2] - 公司此前于7月31日发布的全年预测未包含第二季度之后可能产生的此类费用[3] 公司运营与战略 - 公司近期开始建设价值195亿美元的新原料药生产工厂 预计2027年全面投产[4] - 新工厂将专注于免疫学、肿瘤学和神经科学领域的药物生产[4] - 公司依赖新免疫药物Skyrizi和Rinvoq来抵消明星产品Humira因生物类似药竞争导致的销售额下滑[5] 市场表现与背景 - 消息公布后 公司股价在盘后交易中下跌近1%至2320美元[1] - 为加强研发管线 公司自2023年以来在收购上花费超过200亿美元[5]

市场前景与驱动因素 - 股市上行趋势保持完好，除非政府停摆持续超过两周才可能损害消费者信心[2] - 股票价格由企业盈利和利率驱动，尽管消费者支出有所放缓，但企业盈利依然强劲，部分得益于对人工智能等领域的投资[4] - 关税的影响预计将在第四季度假日零售季明显显现，其影响类似于一次性的进口税，但美联储不应因此过度收紧信贷或推迟降息[3] - 预计美联储将在10月和12月各降息25个基点[3] 选股方法论 - 筛选标准为远期市盈率低于15倍的廉价股票，并根据对冲基金持仓数量进行升序排列[7] - 关注对冲基金大量持有的股票，因模仿顶级对冲基金的最佳选股策略可跑赢市场[8] 赛诺菲公司分析 - 赛诺菲是一家总部位于法国的全球医疗保健公司，从事药品、疫苗和消费者保健产品的研发、生产和营销[12] - 公司远期市盈率为9.91，有24家对冲基金持有[9] - 公司宣布向赛诺菲风险投资基金追加投资6.25亿美元，使其总资产超过14亿美元，该基金长期专注于生物技术和数字健康初创企业投资[10][11] - 赛诺菲风险基金自2012年成立以来，已在全球约70家公司投资超过8亿美元，投资阶段覆盖早期种子轮到IPO[11] 奥驰亚集团公司分析 - 奥驰亚集团是一家领先的美国烟草公司，为21岁及以上成年消费者提供一系列烟草产品[15] - 公司远期市盈率为12.07，有54家对冲基金持有[13] - 美国银行证券维持对该公司的买入评级，目标股价72美元，看好其与KT&G公司的合作以及在无烟产品领域的增长[13][14] - 分析师认为其LOOP品牌因口味系列和尼古丁含量多样而成为增长机会，并看好其财务优化计划、定价能力提升以及有利的监管框架[14][15]

I wrote back in January that I believed the drug stocks would outperform the general stock market for the first time in years in 2025 . The rationale was quite simple-valuations were conservative yetAnalyst’s Disclosure:I/we have a beneficial long position in the shares of LLY, AZN, NVO, PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business re ...

©2025 Investor's Business Daily, LLC. All Rights Reserved. *Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. Information in Investor's Business Daily is for informational and educational purposes only and s ...